Patents by Inventor Wolfgang Uckert
Wolfgang Uckert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11643468Abstract: An isolated chimeric antigen receptor polypeptide (CAR), wherein the CAR comprises an extracellular antigen-binding domain, comprising an antibody or antibody fragment that binds a human CXC chemokine receptor type 5 (CXCR5) protein. Also disclosed is a nucleic acid molecule encoding the CAR of the invention, a genetically modified immune cell, preferably a T cell, expressing the CAR of the invention and the use of said cell in the treatment of a medical disorder associated with the presence of pathogenic cells expressing CXCR5, preferably pathogenic mature B cells and/or memory B cells, and/or pathogenic T cells and/or T follicular helper cells, in particular mature B cell non-Hodgkin's lymphoma (B-NHL), T cell non-Hodgkin's lymphoma, or autoantibody-dependent autoimmune disease, preferably selected from systemic lupus erythematosus (SLE) or rheumatoid arthritis.Type: GrantFiled: August 23, 2018Date of Patent: May 9, 2023Assignee: Max-Delbrück-Centrum für Molekulare Medizin in der Hemlholtz-GemeinschaftInventors: Uta Höpken, Armin Rehm, Julia Bluhm, Wolfgang Uckert
-
Publication number: 20220267407Abstract: The present invention relates to the filed of immunotherapy, in particular, of Epstein-Barr virus-associated diseases (EBV, also designated Human gammaherpesvirus 4), e.g., cancer or post-transplant lymphoproliferative disease, in particular, to adoptive T cell therapy or T cell receptor (TCR) gene therapy. The invention provides a combination of nucleic acids encoding at least two TCR constructs, or the respective proteins or host cells, wherein each TCR construct is capable of specifically binding to its respective epitope in the context of the respective MHC I, and wherein the epitopes are peptides from different antigens expressed by the same infective agent or cancer, e.g., EBV antigens.Type: ApplicationFiled: February 28, 2020Publication date: August 25, 2022Inventors: Felix LORENZ, Krystyna DUDANIEC, Wolfgang UCKERT
-
Publication number: 20220154191Abstract: A genetically modified cytotoxic T cell includes one or more exogenous nucleic acid molecules encoding a transgenic antigen-targeting construct. Estrogen receptor-binding fragment-associated antigen 9 (EBAG9) activity is inhibited in the cells. The antigen-targeting construct can be a chimeric antigen receptor (CAR) or T cell receptor (TCR). The modified T cell can be used in the treatment of a proliferative disease, in particular for the treatment of hematologic malignancies. A pharmaceutical composition includes the modified T cell, a nucleic acid vector encoding the antigen-targeting construct and an inhibitor of EBAG9, such an RNA interference molecule. An in vitro method can increase the cytolytic activity of a cytotoxic T cell.Type: ApplicationFiled: March 25, 2020Publication date: May 19, 2022Inventors: Armin Rehm, Anthea Wirges, Mario Bunse, Wolfgang Uckert
-
Publication number: 20220089671Abstract: The present invention relates to the field of genetic engineering, in particular, to a transposon-based transfection kit suitable for transfection of primary cells, such as T cells, comprising mRNA encoding a transposase, or reagents for generating mRNA encoding said transposase, as well as minicircle DNA comprising the transposon. The invention also relates to a nucleic acid, preferably, a DNA minicircle, comprising a transposon, wherein the transposon encodes a protein and at least one miRNA, wherein the sequences encoding the miRNA are located in an intron and expression of the protein and the miRNA is regulated by the same promoter. The invention also provides a population of cells obtainable with the method of the invention. Methods of transfection are also provided, as well as medical use, e.g. in immunotherapy, in particular, in adoptive T cell therapy or T cell receptor (TCR) or chimeric antigen receptor (CAR) gene therapy.Type: ApplicationFiled: March 5, 2021Publication date: March 24, 2022Inventors: Wolfgang UCKERT, Mario BUNSE, Julian CLAUSS, Zsuzsanna IZSVÁK
-
Publication number: 20210261947Abstract: The present invention relates to the field of immunotherapy, in particular, to adoptive T cell therapy, T cell receptor (TCR) gene therapy and vaccination. The invention provides a method for preparing a nucleic acid encoding the TCR alpha chain construct (TRA) and TCR beta chain construct (TRB) of a TCR construct specific for an epitope from an antigen presented on major histocompatibility complex (MHC), comprising contacting T cells isolated from a donor with a library of artificial antigen presenting cells (APC) comprising cells expressing all MHC I or MHC II alleles present in the donor, preferably, in K562 cells. The TCR construct can be expressed in a T cell, which is useful for adoptive T cell therapy, e.g., of cancer, viral infections or autoimmune diseases. The invention further provides a method for identifying the epitope recognized by said TCR. Immunogenic epitopes recognized by said TCRs can be used to develop vaccine formulations to induce antigen-specific T cell immunity in patients.Type: ApplicationFiled: May 6, 2021Publication date: August 26, 2021Inventors: Felix LORENZ, Wolfgang UCKERT, Christian ELLINGER, Dolores SCHENDEL
-
Patent number: 11001830Abstract: The present invention relates to the field of immunotherapy, in particular, to adoptive T cell therapy, T cell receptor (TCR) gene therapy and vaccination. The invention provides a method for preparing a nucleic acid encoding the TCR alpha chain construct (TRA) and TCR beta chain construct (TRB) of a TCR construct specific for an epitope from an antigen presented on major histocompatibility complex (MHC), comprising contacting T cells isolated from a donor with a library of artificial antigen presenting cells (APC) comprising cells expressing all MHC I or MHC II alleles present in the donor, preferably, in K562 cells. The TCR construct can be expressed in a T cell, which is useful for adoptive T cell therapy, e.g., of cancer, viral infections or autoimmune diseases. The invention further provides a method for identifying the epitope recognized by said TCR. Immunogenic epitopes recognized by said TCRs can be used to develop vaccine formulations to induce antigen-specific T cell immunity in patients.Type: GrantFiled: March 15, 2016Date of Patent: May 11, 2021Assignees: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT, HELMHOLTZ ZENTRUM MÜNCHEN-DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UNDInventors: Felix Lorenz, Wolfgang Uckert, Christian Ellinger, Dolores Schendel
-
Patent number: 10975136Abstract: The present invention relates to the field of genetic engineering, in particular, to a transposon-based transfection kit suitable for transfection of primary cells, such as T cells, comprising mRNA encoding a transposase, or reagents for generating mRNA encoding said transposase, as well as minicircle DNA comprising the transposon. The invention also relates to a nucleic acid, preferably, a DNA minicircle, comprising a transposon, wherein the transposon encodes a protein and at least one miRNA, wherein the sequences encoding the miRNA are located in an intron and expression of the protein and the miRNA is regulated by the same promoter. The invention also provides a population of cells obtainable with the method of the invention. Methods of transfection are also provided, as well as medical use, e.g. in immunotherapy, in particular, in adoptive T cell therapy or T cell receptor (TCR) or chimeric antigen receptor (CAR) gene therapy.Type: GrantFiled: March 15, 2017Date of Patent: April 13, 2021Assignee: Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-GemeinschaftInventors: Wolfgang Uckert, Mario Bunse, Julian Clauss, Zsuzsanna Izsvák
-
Publication number: 20200339653Abstract: The present invention is directed to a high affinity T cell receptor (TCR) against a tumor-associated antigen, an isolated nucleic acid molecule encoding same, a T cell expressing said TCR, and a pharmaceutical composition for use in the treatment of diseases involving malignant cells expressing said tumor-associated antigen.Type: ApplicationFiled: March 17, 2020Publication date: October 29, 2020Inventors: Dolores Jean SCHENDEL, Susanne WILDE, Bernhard FRANKENBERGER, Wolfgang UCKERT
-
Publication number: 20200216550Abstract: An isolated chimeric antigen receptor polypeptide (CAR), wherein the CAR comprises an extracellular antigen-binding domain, comprising an antibody or antibody fragment that binds a human CXC chemokine receptor type 5 (CXCR5) protein. Also disclosed is a nucleic acid molecule encoding the CAR of the invention, a genetically modified immune cell, preferably a T cell, expressing the CAR of the invention and the use of said cell in the treatment of a medical disorder associated with the presence of pathogenic cells expressing CXCR5, preferably pathogenic mature B cells and/or memory B cells, and/or pathogenic T cells and/or T follicular helper cells, in particular mature B cell non-Hodgkin's lymphoma (B-NHL), T cell non-Hodgkin's lymphoma, or autoantibody-dependent autoimmune disease, preferably selected from systemic lupus erythematosus (SLE) or rheumatoid arthritis.Type: ApplicationFiled: August 23, 2018Publication date: July 9, 2020Inventors: Uta HÖPKEN, Armin REHM, Julia BLUHM, Wolfgang UCKERT
-
Patent number: 10626159Abstract: The present invention is directed to a high affinity T cell receptor (TCR) against a tumor-associated antigen, an isolated nucleic acid molecule encoding the same, a T cell expressing the TCR, and a pharmaceutical composition for use in the treatment of diseases involving malignant cells expressing the tumor-associated antigen.Type: GrantFiled: November 27, 2017Date of Patent: April 21, 2020Assignees: MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN, Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)Inventors: Dolores Jean Schendel, Susanne Wilde, Bernhard Frankenberger, Wolfgang Uckert
-
Publication number: 20190307797Abstract: The invention relates to an isolated chimeric antigen receptor polypeptide (CAR), wherein the CAR comprises an extracellular antigen-binding domain, comprising an antibody or antibody fragment that binds a B Cell Maturation Antigen (BCMA) polypeptide. The CAR preferably binds an epitope comprising one or more amino acids of residues 13 to 32 of the N-terminus of human BCMA. The invention further relates to a nucleic acid molecule encoding the CAR of the invention, a genetically modified immune cell, preferably a T cell, expressing the CAR of the invention and the use of said cell in the treatment of a medical disorder associated with the presence of pathogenic B cells, such as a disease of plasma cells, memory B cells and/or mature B cells, in particular multiple myeloma, non-Hodgkin's lymphoma or autoantibody-dependent autoimmune diseases.Type: ApplicationFiled: June 7, 2017Publication date: October 10, 2019Inventors: Armin Rehm, Uta Elisabeth Höpken, Julia Bluhm, Wolfgang Uckert, Elisa Kieback, Stephen Marino
-
Publication number: 20190071484Abstract: The present invention relates to the field of genetic engineering, in particular, to a transposon-based transfection kit suitable for transfection of primary cells, such as T cells, comprising mRNA encoding a transposase, or reagents for generating mRNA encoding said transposase, as well as minicircle DNA comprising the transposon. The invention also relates to a nucleic acid, preferably, a DNA minicircle, comprising a transposon, wherein the transposon encodes a protein and at least one miRNA, wherein the sequences encoding the miRNA are located in an intron and expression of the protein and the miRNA is regulated by the same promoter. The invention also provides a population of cells obtainable with the method of the invention. Methods of transfection are also provided, as well as medical use, e.g. in immunotherapy, in particular, in adoptive T cell therapy or T cell receptor (TCR) or chimeric antigen receptor (CAR) gene therapy.Type: ApplicationFiled: March 15, 2017Publication date: March 7, 2019Inventors: Wolfgang UCKERT, Mario BUNSE, Julian CLAUSS, Zsuzsanna IZSVÁK
-
Publication number: 20180162921Abstract: The present invention is directed to a high affinity T cell receptor (TCR) against a tumor-associated antigen, an isolated nucleic acid molecule encoding same, a T cell expressing said TCR, and a pharmaceutical composition for use in the treatment of diseases involving malignant cells expressing said tumor-associated antigen.Type: ApplicationFiled: November 27, 2017Publication date: June 14, 2018Inventors: Dolores Jean SCHENDEL, Susanne WILDE, Bernhard FRANKENBERGER, Wolfgang UCKERT
-
Publication number: 20180073013Abstract: The present invention relates to the field of immunotherapy, in particular, to adoptive T cell therapy, T cell receptor (TCR) gene therapy and vaccination. The invention provides a method for preparing a nucleic acid encoding the TCR alpha chain construct (TRA) and TCR beta chain construct (TRB) of a TCR construct specific for an epitope from an antigen presented on major histocompatibility complex (MHC), comprising contacting T cells isolated from a donor with a library of artificial antigen presenting cells (APC) comprising cells expressing all MHC I or MHC II alleles present in the donor, preferably, in K562 cells. The TCR construct can be expressed in a T cell, which is useful for adoptive T cell therapy, e.g., of cancer, viral infections or autoimmune diseases. The invention further provides a method for identifying the epitope recognized by said TCR. Immunogenic epitopes recognized by said TCRs can be used to develop vaccine formulations to induce antigen-specific T cell immunity in patients.Type: ApplicationFiled: March 15, 2016Publication date: March 15, 2018Inventors: Felix LORENZ, Wolfgang UCKERT, Christian ELLINGER, Dolores SCHENDEL
-
Patent number: 9862755Abstract: The present invention is directed to a high affinity T cell receptor (TCR) against a tumor-associated antigen, an isolated nucleic acid molecule encoding same, a T cell expressing said TCR, and a pharmaceutical composition for use in the treatment of diseases involving malignant cells expressing said tumor-associated antigen.Type: GrantFiled: March 25, 2014Date of Patent: January 9, 2018Assignee: MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZINInventors: Dolores Jean Schendel, Susanne Wilde, Bernhard Frankenberger, Wolfgang Uckert
-
Publication number: 20170044233Abstract: The present invention is directed to a kit-of-parts or composition containing nucleic acid sequences coding for high-avidity, allo-restricted TCR, wherein the TCR are independently directed against the tyrosinase antigen, the melan-A antigen and the survivin antigen. The invention is further directed to a kit-of-parts or composition containing at least three groups of transgenic lymphocytes transformed with vectors coding for TCR against said antigens. Furthermore, the present invention provides a pharmaceutical composition and its use in the treatment of diseases involving malignant cells expressing said tumor-associated antigens. The invention further relates to a nucleic acid molecule coding for a TCR that recognizes the survivin antigen, a TCR encoded thereby and a T cell expressing said TCR. Further, the invention discloses a vector, a cell and a pharmaceutical composition encoding/containing same and their use in the treatment of diseases involving malignant cells expressing survivin.Type: ApplicationFiled: July 7, 2016Publication date: February 16, 2017Inventors: Dolores J. SCHENDEL, Susanne WILDE, Bernhard FRANKENBERGER, Wolfgang UCKERT
-
Patent number: 9409969Abstract: The present invention is directed to a kit-of-parts or composition containing nucleic acid sequences coding for high-avidity, allo-restricted TCR, wherein the TCR are independently directed against the tyrosinase antigen, the melan-A antigen and the survivin antigen. The invention is further directed to a kit-of-parts or composition containing at least three groups of transgenic lymphocytes transformed with vectors coding for TCR against said antigens. Furthermore, the present invention provides a pharmaceutical composition and its use in the treatment of diseases involving malignant cells expressing said tumor-associated antigens. The invention further relates to a nucleic acid molecule coding for a TCR that recognizes the survivin antigen, a TCR encoded thereby and a T cell expressing said TCR. Further, the invention discloses a vector, a cell and a pharmaceutical composition encoding/containing same and their use in the treatment of diseases involving malignant cells expressing survivin.Type: GrantFiled: February 9, 2010Date of Patent: August 9, 2016Assignees: Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH), MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZINInventors: Dolores J. Schendel, Susanne Wilde, Bernhard Frankenberger, Wolfgang Uckert
-
Publication number: 20160222080Abstract: The present invention is directed to a functional T cell receptor (TCR) fusion protein (TFP) recognizing and binding to at least one MHC-presented epitope, and containing at least one amino acid sequence recognizing and binding an antigen. The present invention is further directed to an isolated nucleic acid molecule encoding the same, a T cell expressing said TFP, and a pharmaceutical composition for use in the treatment of diseases involving malignant cells expressing said tumor-associated antigen.Type: ApplicationFiled: December 16, 2015Publication date: August 4, 2016Inventors: Elisa KIEBACK, Jehad CHARO, Thomas BLANKENSTEIN, Wolfgang UCKERT, Cynthia PEREZ
-
Patent number: 9133264Abstract: The present invention relates to a method for selecting a host cell population expressing a functional fusion protein comprising at least one epitope-providing amino acid sequence (epitope-tag) and the amino acid sequence of a protein that is expressed on the surface of said host cell. Preferably, the amino acid sequence comprises an alpha or beta chain of a T-cell receptor. The present invention further relates to uses of said functional T-cell receptor (TCR) alpha or beta chain fusion protein in medicine, in particular in adoptive transfer.Type: GrantFiled: June 22, 2007Date of Patent: September 15, 2015Assignee: MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (MDC) BERLIN-BUCHInventors: Thomas Blankenstein, Wolfgang Uckert, Elisa Kieback, Jehad Charo
-
Publication number: 20140348805Abstract: The present invention is directed to a high affinity T cell receptor (TCR) against a tumor-associated antigen, an isolated nucleic acid molecule encoding same, a T cell expressing said TCR, and a pharmaceutical composition for use in the treatment of diseases involving malignant cells expressing said tumor-associated antigen.Type: ApplicationFiled: March 25, 2014Publication date: November 27, 2014Applicant: Max-Delbrueck-Centrum fur Molekulare Medizin Berlin-BuchInventors: Dolores Jean Schendel, Susanne Wilde, Bernhard Frankenberger, Wolfgang Uckert